IDH1 and central nervous system cancer: IDH1 mutations are predominately found in WHO grade II and III gliomas (70% of cases) compared to grade IV GBM (12% of cases), and GBM which harbor the IDH1 mutation lead to significantly longer survival times of greater than two-fold [50,51].